帕罗西汀联合普拉克索治疗对帕金森患者血清胱抑素C、白细胞介素-1β的影响

Study on the effect of paroxetine combined with pramipexole treatment on serum cystatin C and interleukin-1βin Parkinson’s patients

目的分析帕罗西汀联合普拉克索治疗对帕金森患者血清胱抑素C(CysC)、白细胞介素-1β(IL-1β)的影响。方法选取新密市某医院2018年10月—2020年12月诊治的128例帕金森患者为研究对象,采用随机数字表法分为单药组(64例)和联药组(64例),单药组患者给予普拉克索治疗,联药组患者给予帕罗西汀联合普拉克索治疗,2组患者均持续治疗8周。比较2组患者临床疗效及不良反应发生情况,比较2组患者治疗前后的汉密尔顿抑郁量表(HAMD)评分、血清Cys C及IL-1β水平。结果联药组患者治疗总有效率为96.87%,高于单药组的78.12%,差异有统计学意义(χ^(2)=10.286,P=0.001)。治疗前,2组患者HAMD评分比较,差异无统计学意义(P>0.05);治疗后,2组患者HAMD评分均低于治疗前,且联药组明显低于单药组,差异均有统计学意义(P<0.05)。治疗前,2组患者血清Cys C及IL-1β水平比较,差异无统计学意义(P>0.05);治疗后,2组患者血清Cys C及IL-1β水平均低于治疗前,且联药组明显低于单药组,差异均有统计学意义(P<0.05)。联药组患者不良反应发生率为6.25%,高于单药组的4.69%,但差异无统计学意义(P>0.05)。结论帕罗西汀联合普拉克索治疗,可有效缓解帕金森病患者的抑郁症状,降低血清Cys CIL-1、β水平,且不良反应较少,安全性较高,值得临床推广使用。

Objective To analyze the effects of paroxetine combined with pramipexole on serum cystatin C(CysC)and interleukin-1β(IL-1β)in Parkinson’s patients.Methods One hundred and twenty-eight Parkinson’s patients treated in a hospital in Xinmi from October 2018 to December 2020 were selected for the study and were divided into single-drug group(64 cases)and combination group(64 cases)using the random number table method.Patients in the single-drug group were given pramipexole treatment and patients in the combination drug group were given paroxetine combined with pramipexole.Both groups were treated for 8 weeks.The clinical efficacy,occurrence of adverse effects,Hamilton Depression Rating Scale(HAMD)scores,serum CysC and IL-1βlevels were compared between the two groups before and after treatment.Results The overall treatment efficiency of the patients in the combination group was 96.87%,which was higher than that of the single-drug group(78.12%).and the difference was statistically significant(χ^(2)=10.286,P=0.001).Before,treatment,there was no statistically significant difference between the HAMD scores of the 2 groups(P>0.05);after treatment,the HAMD scores of the 2 groups were significantly lower than before treatment,and the combination group had a significantly lower score than the single-drug group(P<0.05).Before treatment,there was no statistically significant difference between the serum CysC and IL-1βlevels of the two groups(P>0.05);after treatment,the serum CysC and IL-1βlevels of the two groups were significantly lower than before treatment,and the combination group had significantly lower levels than the single drug group(P<0.05).The incidence of adverse reactions was 6.25%in the combination group,which was higher than that of 4.69%in the single-drug group,but the difference was not statistically significant(P>0.05).Conclusion Paroxetine combined with pramipexole treatment can effectively relieve depressive symptoms and reduce serum CysC and IL-1βlevels in patients with Parkinson’s disease with fewer adverse effects and higher safety,which is worthy of wider clinical application.